Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shot up 5.4% on Monday . The stock traded as high as $4.30 and last traded at $4.08. 439,390 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 855,567 shares. The stock had previously closed at $3.87.

Several equities analysts have commented on CRVS shares. Zacks Investment Research raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Mizuho reiterated a “buy” rating and issued a $7.00 price target on shares of Corvus Pharmaceuticals in a research note on Thursday, July 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.25.

The company has a debt-to-equity ratio of 0.04, a current ratio of 5.24 and a quick ratio of 5.24. The business has a 50 day moving average price of $3.86 and a 200 day moving average price of $3.26. The stock has a market capitalization of $114.39 million, a PE ratio of -2.79 and a beta of 2.13.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.08). On average, equities analysts expect that Corvus Pharmaceuticals Inc will post -1.27 earnings per share for the current year.

In other news, major shareholder Holdings A/S Novo sold 1,538,062 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $5.31, for a total transaction of $8,167,109.22. Following the transaction, the insider now directly owns 2,130,938 shares of the company’s stock, valued at $11,315,280.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 45.12% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRVS. Two Sigma Advisers LP grew its position in Corvus Pharmaceuticals by 27.7% in the 2nd quarter. Two Sigma Advisers LP now owns 36,880 shares of the company’s stock worth $100,000 after purchasing an additional 8,000 shares during the period. Russell Investments Group Ltd. increased its position in Corvus Pharmaceuticals by 29.6% during the second quarter. Russell Investments Group Ltd. now owns 39,171 shares of the company’s stock valued at $106,000 after acquiring an additional 8,951 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Corvus Pharmaceuticals during the 1st quarter valued at about $52,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Corvus Pharmaceuticals by 4.7% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 85,604 shares of the company’s stock worth $181,000 after purchasing an additional 3,804 shares during the period. 73.05% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

See Also: What is the CAC 40 Index

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.